Canada markets closed

Iovance Biotherapeutics, Inc. (2LB.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
10.38-1.98 (-15.99%)
At close: 05:11PM CEST
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

Currency in USD. All numbers in thousands
Breakdown
ttm
2023-12-31
2022-12-31
2021-12-31
2020-12-31
Total Revenue
1,189
1,189
0
0
0
Cost of Revenue
10,755
10,755
0
0
-
Gross Profit
-9,566
-9,566
0
0
-
Operating Expenses
Research Development
344,077
344,077
294,781
259,039
201,727
Selling General and Administrative
106,916
106,916
104,097
83,664
60,210
Total Operating Expenses
450,993
450,993
398,878
342,703
261,937
Operating Income or Loss
-460,559
-460,559
-398,878
-342,703
-261,937
Income Before Tax
-447,516
-447,516
-395,893
-342,252
-259,581
Income Tax Expense
-3,479
-3,479
0
0
-
Income from Continuing Operations
-444,037
-444,037
-395,893
-342,252
-259,581
Net Income
-444,037
-444,037
-395,893
-342,252
-259,581
Net Income available to common shareholders
-444,037
-444,037
-395,893
-342,252
-259,581
Basic EPS
-2.08
-1.89
-2.49
-2.23
-1.88
Diluted EPS
-2.08
-1.89
-2.49
-2.23
-1.88
Basic Average Shares
212,292
235,131
159,259
153,406
138,301
Diluted Average Shares
212,292
235,131
159,259
153,406
138,301